Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply
JAMA
.
2016 Nov 22;316(20):2152.
doi: 10.1001/jama.2016.16292.
Authors
Dhruv S Kazi
1
,
Andrew E Moran
2
,
Kirsten Bibbins-Domingo
1
Affiliations
1
Department of Medicine, University of California, San Francisco.
2
College of Physicians and Surgeons, Columbia University, New York, New York.
PMID:
27893125
DOI:
10.1001/jama.2016.16292
No abstract available
Publication types
Letter
Comment
MeSH terms
Cost-Benefit Analysis*
Humans
Proprotein Convertases*
Serine Endopeptidases
Substances
Proprotein Convertases
Serine Endopeptidases